Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
| ▸ | PRKCA | P17252 | 5/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10071373 | 1.00 | SMN1; SMN2 (0.40) | SMN1; SMN2KMT2APAOXHPGDHTT | |
| SCHEMBL12896267 | 1.00 | SMN1; SMN2 (0.40) | SMN1; SMN2KMT2APAOXHPGDHTT | |
| SCHEMBL10071372 | 0.98 | SMN1; SMN2 (0.38) | SMN1; SMN2KMT2APAOXHPGDHTT | |
| SCHEMBL829438 | 0.95 | SMN1; SMN2 (0.35) | SMN1; SMN2KMT2APAOXHPGDHTT | |
| SCHEMBL19676775 | 0.93 | PAOX (0.37) | SMN1; SMN2KMT2APAOXHPGDHTT | |
| SCHEMBL905722 | 0.91 | SMN1; SMN2 (0.42) | SMN1; SMN2KMT2AHPGDHTTGAA | |
| SCHEMBL905700 | 0.91 | SMN1; SMN2 (0.42) | SMN1; SMN2KMT2AHPGDHTTGAA | |
| SCHEMBL905404 | 0.91 | SMN1; SMN2 (0.42) | SMN1; SMN2KMT2AHPGDHTTGAA | |
| SCHEMBL4960230 | 0.91 | SMN1; SMN2 (0.42) | SMN1; SMN2KMT2AHPGDHTTGAA | |
| SCHEMBL379163 | 0.91 | SMN1; SMN2 (0.42) | SMN1; SMN2KMT2AHPGDHTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2247645-B1 | CROSSLINKED POLYALKYLENEIMINE HYDROGELS WITH TUNABLE DEGRADATION RATES | HYPERBRANCH MEDICAL TECH INC (US) | 2017-12-06 | — | — | EP | disclosed |
| US-20170196982-A1 | MACROLIDE DOSAGE FORMS | MICELL TECHNOLOGIES, INC. (US) | 2017-07-13 | — | — | US | disclosed |
| US-9636309-B2 | Macrolide dosage forms | MICELL TECHNOLOGIES, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-20150087671-A1 | LOW BURST SUSTAINED RELEASE LIPOPHILIC AND BIOLOGIC AGENT COMPOSITIONS | MICELL SPV I LLC | 2015-03-26 | — | — | US | disclosed |
| US-8846022-B2 | Crosslinked polyalkyleneimine hydrogels with tunable degradation rates | HYPERBRANCH MEDICAL TECHNOLOGY, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8410189-B2 | Crosslinked polyalkyleneimine hydrogels with tunable degradation rates | HYPERBRANCH MEDICAL TECHNOLOGY, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| WO-2012034079-A2 | MACROLIDE DOSAGE FORMS | MICELL TECHNOLOGIES, INC. (US) | 2012-03-15 | — | — | WO | disclosed |
| US-20110044932-A1 | Crosslinked Polyalkyleneimine Hydrogels with Tunable Degradation Rates | HYPERBRANCH MEDICAL TECHNOLOGY, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20090215923-A1 | Crosslinked Polyalkyleneimine Hydrogels with Tunable Degradation Rates | HYPERBRANCH MEDICAL TECHNOLOGY, INC. (US) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087671-A1 | LOW BURST SUSTAINED RELEASE LIPOPHILIC AND BIOLOGIC AGENT COMPOSITIONS | LIPA, LTA, LPXN | SMN1; SMN2 4347/4885KMT2A 4500/4885PAOX 2301/4885 |
| US-20170196982-A1 | MACROLIDE DOSAGE FORMS | MRPL21, MRPL37, MLN | SMN1; SMN2 1699/4885KMT2A 4454/4885PAOX 2822/4885 |
| US-20110044932-A1 | Crosslinked Polyalkyleneimine Hydrogels with Tunable Degradation Rates | XRCC5, ADM2, XRCC6 | SMN1; SMN2 4346/4885KMT2A 2769/4885PAOX 2961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.